PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
NCT ID: NCT06247163
Last Updated: 2024-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30 participants
OBSERVATIONAL
2024-02-22
2029-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer
NCT04758481
Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC
NCT02473133
Stereotactic Radiotherapy With Different Fractionation Modes for the Early Lung Cancer
NCT05802641
SBRT/RT in Oligometastatic Stage IV NSCLC
NCT05647590
Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer
NCT00016211
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET based Raditherapy boost
An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Limited disease
Exclusion Criteria
* Further tumor diagnosis
* ECOG 3 or worse
* Extensive disease
* stage IV
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Essen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maja Guberina
PD Dr. med. (MD) Maja Guberina, specialist in radiation oncology, senior consultant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Essen
Essen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-11560-BO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.